Evidence map›Paper›PMID 34820749›Full record

ArticleMolecular biology reports2022

Kaempferol sensitizes tumor necrosis factor-related apoptosis-inducing ligand-resistance chronic myelogenous leukemia cells to apoptosis.

Raedeh Saraei, Heshu Sulaiman Rahman, Masoud Soleimani, Mohammad Asghari-Jafarabadi, Adel Naimi, Ali Hassanzadeh, Saeed Solali

Abstract read
PubMed Publisher
In one paragraph

Article in Molecular biology reports, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed, 1 pooled it
0.6field-weighted citation impact, top 32% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 1 synthesis or guideline pooled it, 10 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Article
  4. Article
  5. Review
  6. Review
  7. Article
  8. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 5 institutions in 2 countries.

Raedeh SaraeiImmunology Research Center, Tabriz University of Medical Sciences, Tabriz, Iran.ORCID http://orcid.org/0000-0003-0612-0815
Heshu Sulaiman RahmanCollege of Medicine, University of Sulaimani, Sulaimaniyah, Iraq.
Masoud SoleimaniHematology Department, Faculty of Medical Sciences, Tarbiat Modares University, Tehran, Iran.
Mohammad Asghari-JafarabadiDepartment of Statistics and Epidemiology, School of Medicine, Zanjan University of Medical Sciences, Zanjan, Iran.ORCID http://orcid.org/0000-0003-3284-9749
Adel NaimiCellular and Molecular Research Center, Sabzevar University of Medical Sciences, Sabzevar, Iran.ORCID http://orcid.org/0000-0001-6683-6845
Ali HassanzadehImmunology Research Center, Tabriz University of Medical Sciences, Tabriz, Iran.ORCID http://orcid.org/0000-0002-7530-1145
Saeed SolaliImmunology Research Center, Tabriz University of Medical Sciences, Tabriz, Iran. ssolali@gmail.com.ORCID http://orcid.org/0000-0002-6487-3551
Tabriz University of Medical Sciences · IRKomar University of Science and Technology · IQSabzevar University of Medical Sciences · IRTarbiat Modares University · IRZanjan University of Medical Sciences · IR

Funding

tabriz university of medical sciences 57664
6 · The paper itself

Abstract

backgroundThe tumor necrosis factor (TNF)-related apoptosis-inducing ligand, TRAIL, an apoptosis-inducing cytokine, has attracted much attention in the treatment of cancer for its selective toxicity to malignant rather than normal cells. However, the apoptosis-inducing ability of TRAIL is weaker than expected primarily due to cancer cell resistance. As one of the dietary flavonoids, kaempferol, has been shown to be antiproliferative and might have a protective effect against TRAIL resistance, particularly for hematologic malignancies. METHODS AND

resultsHere, we studied the potential of kaempferol to enhance the TRAIL-induced cytotoxicity and apoptosis in human chronic myelogenous leukemia (CML) cell line K-562, as well as the expression of specific genes with impact on TRAIL signal regulation. Analysis of flowcytometry data showed that treatment with kaempferol did enhance sensitivity of CML cells to pro-apoptotic effects of anti-TRAIL antibody. Although the gene expression levels were heterogeneous, cFLIP, cIAP1 and cIAP2 expression were generally downregulated where co-treatment of kaempferol and TRAIL was employed and these effects appeared to be dose-dependent. We further demonstrated that the expression of death receptors 4 and 5 tended to increase subsequent to the combination treatment.

conclusionsConsequently, it is reasonable to conclude that sensitization of chronic leukemia cells to TRAIL by kaempferol in vitro should be considered as a way of focusing clinical attention on leukemia therapy.

Indexed as

Antineoplastic Combined Chemotherapy ProtocolsApoptosis Regulatory ProteinsBaculoviral IAP Repeat-Containing 3 ProteinCASP8 and FADD-Like Apoptosis Regulating ProteinCell Line, TumorCell ProliferationCell SurvivalDose-Response Relationship, DrugGene Expression Regulation, NeoplasticHumansInhibitor of Apoptosis ProteinsK562 CellsKaempferolsLeukemia, Myelogenous, Chronic, BCR-ABL PositiveTNF-Related Apoptosis-Inducing LigandUbiquitin-Protein LigasesApoptosis Regulatory ProteinsBaculoviral IAP Repeat-Containing 3 ProteinBIRC2 protein, humanBIRC3 protein, humanCASP8 and FADD-Like Apoptosis Regulating ProteinCFLAR protein, humanInhibitor of Apoptosis ProteinskaempferolKaempferolsTNF-Related Apoptosis-Inducing LigandUbiquitin-Protein LigasescFLIPChronic myelogenous leukemia (CML)cIAPDeath receptorsKaempferolTumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL)

Identifiers

PMID34820749
OpenAlexW3215670919

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.